HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Meta-analysis of efficacy and safety of liver transplantation in treating cholangiocarcinoma].

AbstractOBJECTIVE:
To evaluate the therapeutic efficacy and safety of liver transplantation for patients with cholangiocarcinoma.
METHODS:
According to the requirements of Cochrane systematic review, a thorough literature search was performed in Pubmed/Medline, Embase and Cochrane Central Register electronic databases ranged between 1995 and 2009 in terms of the key words "liver transplantation", and "cholangiocarcinoma" or "cholangiocellular carcinoma" or "bile duct cancer". And restricted the articles published in the English language. Two reviewers independently screened the studies for eligibility, evaluated the quality and extracted the data from the eligible studies with confirmation by cross-checking. Data were processed for a meta-analysis by Stata 10 software with 1-, 3-, 5-year survival rates and incidence of complications.
RESULTS:
A total of 14 clinical trials containing 605 patients were finally enrolled in this study. The overall 1-, 3-, 5-year pooled survival rates were 73% (95%CI: 0.65 - 0.80), 42% (95%CI: 0.33 - 0.51) and 39% (95%CI: 0.28 - 0.51), respectively. Of note, preoperative adjuvant therapies (OLT-PAT group) rendered the transplanted individuals comparably favorable outcomes with 1-, 3-, 5-year pooled survival rates of 83% (95%CI: 0.57 - 0.98), 57% (95%CI: 0.18 - 0.92) and 65% (95%CI: 0.40 - 0.87), respectively. In addition, the overall pooled incidence of complications was 62% (95%CI: 0.44 - 0.78), among which that of OLT-PAT group (58%, 95%CI: 0.20 - 0.92) was relatively acceptable compared to those of liver transplantation alone (61%, 95%CI: 0.33 - 0.85) and liver transplantation with extended bile duct resection (78%, 95%CI: 0.55 - 0.94).
CONCLUSIONS:
In comparison to curative resection of cholangiocarcinoma with the 5-year survival rate reported from 20% to 40%, the role of liver transplantation alone is so limited, but neoadjuvant radiochemotherapy combined with liver transplantation can bring better short- and long-term prognosis.
AuthorsJin-yang Gu, Jian-ling Bai, Xiao-lei Shi, Jian-xin Zhou, Yu-dong Qiu, Ya-fu Wu, Chun-ping Jiang, Xi-tai Sun, Fang-gui Xu, Yue Zhang, Yi-tao Ding
JournalZhonghua wai ke za zhi [Chinese journal of surgery] (Zhonghua Wai Ke Za Zhi) Vol. 49 Issue 4 Pg. 351-6 (Apr 01 2011) ISSN: 0529-5815 [Print] China
PMID21612703 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)
Topics
  • Bile Duct Neoplasms (surgery)
  • Cholangiocarcinoma (surgery)
  • Clinical Trials as Topic
  • Humans
  • Liver Transplantation
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: